알테오젠

196170KOSDAQ자연과학 및 공학 연구개발업

57.5 / 100

Reference Date: 2026-04-13

Financial Score28.0 / 40

News Sentiment12.5 / 25

Momentum7.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health and ROE is above the industry average is also solid. Roughly flat over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Alteogen is a biotech company leveraging platform technologies like Hybrozyme™, NexP™, and NexMab™ to develop and commercialize biopharmaceuticals, with licensing agreements with global pharma firms such as MSD and AstraZeneca, ensuring sustainable revenue through upfront fees, milestones, and royalties. Its key product ALT-B4 offers subcutaneous injection advantages over IV formulations, while its biosimilar business collaborates with Qilu Pharmaceutical to expand market reach.

Number of Employees

161people

Average Salary

149.1M KRW

Score Calculation Basis

Detailed Financial Score

PER

136.26Industry Average 120.073.0Point

Higher than industry avg (caution)

PBR

—Industry Average 3.823.5Point

ROE

39.85Industry Average -32.113.5Point

Well below industry avg

Debt Ratio

1.02Industry Average 7.528.0Point

Half of industry avg (excellent)

Trend 2023~202510.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲58.2% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲340.9% (2-year basis)

ROE Trend

4.0 / 4

Avg ROE 22.1% (improving, 3yr)

Detailed News Sentiment

10 totalPositive 0Neutral 5Negative 0Average Sentiment Score 50

Detailed Momentum

52-week position1.0Point

Near 52w low (18%, downtrend)

Current 361,500Won52-week high 559,00052-week low 317,500

1-month return3.0Point

1m 0% (flat)

Volume trend3.0Point

Volume flat

Detailed Disclosure

10 totalPositive 0Neutral 10Negative 0

Neutral주식등의대량보유상황보고서(일반)2026-04-07
Neutral기업설명회(IR)개최2026-04-07
Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-04-01
Neutral정기주주총회결과2026-03-31
Neutral투자판단관련주요경영사항 (재조합 인간 히알루로니다제 제품 ALT-B4 독점적 라이선스 계약 체결)2026-03-25